Akorn to Pay $7.9 Million to Resolve False Claims Allegations

Akorn Operating Company LLC, a pharmaceutical company based in Illinois, has agreed to pay $7.9 million to resolve allegations that it caused the submission of false claims to Medicare Part D, the Department of Justice said Thursday.

The company allegedly continued to sell three generic drugs under obsolete Rx-only labels after the brand-name drugs had been converted to over-the-counter products, conduct that would violate the False Claims Act, the DOJ said.

The allegations were originally brought, in part, by a whistleblower, who will receive about $946,000 from the recovery, the department said.

This story was produced by Bloomberg Law Automation. ...